Synaptogenic effect of APP -Swedish mutation in familial Alzheimer’s disease
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Mutations in β-amyloid (Aβ) precursor protein ( APP ) cause familial Alzheimer’s disease (AD) probably by enhancing Aβ peptides production from APP. An antibody targeting Aβ (aducanumab) was approved as an AD treatment; however, some Aβ antibodies have been reported to accelerate, instead of ameliorating, cognitive decline in individuals with AD. Using conditional APP mutations in human neurons for perfect isogenic controls and translational relevance, we found that the APP -Swedish mutation in familial AD increased synapse numbers and synaptic transmission, whereas the APP deletion decreased synapse numbers and synaptic transmission. Inhibition of BACE1, the protease that initiates Aβ production from APP, lowered synapse numbers, suppressed synaptic transmission in wild-type neurons, and occluded the phenotype of APP -Swedish–mutant neurons. Modest elevations of Aβ, conversely, elevated synapse numbers and synaptic transmission. Thus, the familial AD-linked APP -Swedish mutation under physiologically relevant conditions increased synaptic connectivity in human neurons via a modestly enhanced production of Aβ. These data are consistent with the relative inefficacy of BACE1 and anti-Aβ treatments in AD and the chronic nature of AD pathogenesis, suggesting that AD pathogenesis is not simply caused by overproduction of toxic Aβ but rather by a long-term effect of elevated Aβ concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Swedish mutation is pathogenic and is associated with elevated secretion of Aβ and neuronal abnormality [197]”
From Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations (2024) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“The key consequence of the Swedish mutation is thought to be an enhancement of APP cleavage by BACE1, leading to increased A β production (39–40, 49 ), as Chronic treatment of WT human neurons with the BACE1 inhibitor LY2886721 (50–51) suppressed production of A β and of the secreted extracellular…”
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 1×
“consistent with increased synaptic function (60).”
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 1×
“For example, A β increases Ca 2+ influx in cultured neurons and activates synaptic transmission and presynaptic facilitation in mouse hippocampal cultures and slices (28–31), and A β is required in young rats for memory stabilization (32).”
Rapid single-step induction of functional neurons from human pluripotent stem cells
Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., Marro, S., Patzke, C., Acuna, C., Covy, J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.029 · Cited by 1,644 · cited 1×
“S2 for characterization) (45) and infected the developing postmitotic neurons with viruses expressing Flp or Cre recombinase.”
Self-citationShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“A potential role of A β in promoting synaptic function is unexpected given the vast literature suggesting the opposite, albeit on the basis of experiments applying rather high A β concentrations to rodent neurons (52–54).”
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253 · cited 2×
“Studies in human and mouse neurons often involved high concentrations of A β and were performed under conditions that made control for genetic background and for clonal variation difficult (41–43).”
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125 · cited 4×
“ApoE4 also increases the size of endosomes in human neurons (44), similar to endogenous A β in our experiments.”
InfluentialNeurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740
The β-Secretase BACE1 in Alzheimer’s Disease
Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694
Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592 · cited 1×
“For example, transgenic mice overexpressing human APP carrying the so called “Swedish” mutation (K595N/ M596L) that increases Aβ and causes early-onset AD in patients (13) exhibit synapse loss and a decrease in synaptic transmission (14–16).”
Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J., & Hyman, B. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1879-05.2005 · Cited by 550
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · cited 2×
“Although unexpected, our findings offer a potential explanation for the consistent clinical finding that pharmacological suppression of A β by BACE1 inhibition leads to cognitive dysfunction (9–10), which could be due to a loss of synapses.”
ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion
Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017) · Cell · doi:10.1016/j.cell.2016.12.044 · Cited by 528
Self-citationSynapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436 · cited 1×
“Several studies showed that exogenous A β promotes glutamate receptor endocytosis and blocks long-term potentiation (LTP) and memory formation (22–27).”
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
The cell biology of synapse formation
Südhof, T. C. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202103052 · Cited by 358
Self-citationAutism-associated SHANK3 haploinsufficiency causes I h channelopathy in human neurons
Yi, F., Danko, T., Botelho, S. C., Patzke, C., Pak, C., Wernig, M., & Südhof, T. C. (2016) · Science · doi:10.1126/science.aaf2669 · Cited by 313
Self-citationGhatak, S., Dolatabadi, N., Trudler, D., Zhang, X., Wu, Y., Mohata, M., Ambasudhan, R., Talantova, M., & Lipton, S. A. (2019) · eLife · doi:10.7554/elife.50333 · Cited by 227
May, P. C., Willis, B. A., Lowe, S. L., Dean, R. A., Monk, S. A., Cocke, P. J., Audia, J. E., Boggs, L. N., Borders, A. R., Brier, R. A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4129-14.2015 · Cited by 206
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197
Amyloid precursor protein (APP) regulates synaptic structure and function
Tyan, S.-H., Shih, A. Y.-J., Walsh, J. J., Maruyama, H., Sarsoza, F., Ku, L., Eggert, S., Hof, P. R., Koo, E. H., & Dickstein, D. L. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.07.009 · Cited by 191 · cited 2×
“Several studies showed that exogenous A β promotes glutamate receptor endocytosis and blocks long-term potentiation (LTP) and memory formation (22–27).”
Perez-Cruz, C., Nolte, M. W., van Gaalen, M. M., Rustay, N. R., Termont, A., Tanghe, A., Kirchhoff, F., & Ebert, U. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6142-10.2011 · Cited by 172
Revisiting FDA Approval of Aducanumab
Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2110468 · Cited by 162 · cited 1×
“However, the approval of aducanumab raised controversies due to its unclear therapeutic efficacy (7), especially because an antibody to soluble Aβ worsened the cognitive decline in individuals with AD in other clinical trials (8).”
Saura, C. A., Chen, G., Malkani, S., Choi, S.-Y., Takahashi, R. H., Zhang, D., Gouras, G. K., Kirkwood, A., Morris, R. G. M., & Shen, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1247-05.2005 · Cited by 157
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
Presenilins in synaptic function and disease.
Ho, A., & Shen, J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.002 · Cited by 52 · cited 1×
“…it is uncertain whether presenilin mutations causing familial AD are pathogenic because the mutated catalytic subunits of γ -secretase increase the production of A β or change the type of generated A β species or because presenilin mutations induce a partial loss of function of γ -secretase (12).”
Naito, Y., Tanabe, Y., Lee, A. K., Hamel, E., & Takahashi, H. (2017) · Scientific Reports · doi:10.1038/srep42548 · Cited by 42 · cited 1×
“A potential role of A β in promoting synaptic function is unexpected given the vast literature suggesting the opposite, albeit on the basis of experiments applying rather high A β concentrations to rodent neurons (52–54).”
Research works printed but not linked: 26
- 10.1038/sj.emboj.7600061 · DOI · Paper page
- 10.1038/s41591-021-01369-8 · DOI · Paper page
- 10.1007/978-981-32-9358-8_16 · DOI · Paper page
- 10.1523/JNEUROSCI.21-13-04691.2001 · DOI · Paper page
- 10.1016/j.neuron.2016.08.034 · DOI · Paper page
- 10.1523/JNEUROSCI.2009-17.2017 · DOI · Paper page
- 10.1016/j.nbd.2015.10.019 · DOI · Paper page
- 10.1083/jcb.201701045 · DOI · Paper page
- 10.1073/pnas.1614249113 · DOI
- 10.1016/j.neuron.2006.10.035 · DOI · Paper page
- 10.1038/nn.2433 · DOI · Paper page
- 10.1074/jbc.274.42.30322 · DOI · Paper page
- 10.1016/j.cub.2020.02.083 · DOI
- 10.1016/j.molmed.2017.04.001 · DOI
- 10.1016/j.mcn.2015.11.010 · DOI
- 10.1016/j.neuron.2019.07.010 · DOI · Paper page
- 10.1016/j.celrep.2015.03.068 · DOI · Paper page
- 10.1038/s41598-018-20436-8 · DOI
- 10.3389/fnins.2019.01154 · DOI · Paper page
- 10.1523/JNEUROSCI.2994-18.2019 · DOI · Paper page
- 10.1001/jamaneurol.2020.4857 · DOI
- 10.1016/j.neuroscience.2010.04.078 · DOI
- 10.1016/j.cels.2020.11.007 · DOI
- 10.1007/s11064-018-2512-0 · DOI
- 10.1016/j.stem.2015.07.017 · DOI · Paper page
- 10.1172/JCI78612 · DOI
Cited by
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
Wang, J., Fourriere, L., & Gleeson, P. A. (2024) · Biochemical Journal · doi:10.1042/bcj20240056 · Cited by 27
Yesiltepe, M., Yin, T., Tambini, M. D., Breuillaud, L., Zehntner, S. P., & D’Adamio, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1040576 · Cited by 6
Metadata
- Authors
- Zhou, B., Lu, J. G., Siddu, A., Wernig, M., & Südhof, T. C.
- Affiliations
- Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.
- Department of Pathology, Stanford University School of Medicine, 265 Campus Drive, Stanford, CA 94305, USA.
- Venue
- Science Translational Medicine
- Published
- 2022-10-19
- Volume
- 14
- Issue
- 667
- ISSN
- 1946-6234
- 1946-6242
- Cited by
- 106
- References
- 40
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.